免疫排斥 - Wnt/CTNNB1 类预测 HCC 对免疫治疗的耐药性。
Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC.
机构信息
Translational Research in Hepatic Oncology, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Catalonia, Spain.
Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
出版信息
Clin Cancer Res. 2019 Apr 1;25(7):2021-2023. doi: 10.1158/1078-0432.CCR-18-3778. Epub 2019 Jan 7.
Abstract
Next-generation sequencing has provided information on actionable targets and biomarkers of response in oncology. In hepatocellular carcinoma (HCC), Wnt/CTNNB1 mutations characterize the immune-excluded class (cold tumors) and might represent the biomarkers predicting resistance to immune checkpoint inhibitors. Large-scale validation of these data is needed to customize immunotherapy in advanced HCC..
摘要
下一代测序技术为肿瘤学中可采取行动的靶标和反应生物标志物提供了信息。在肝细胞癌（HCC）中，Wnt/CTNNB1 突变特征为免疫排斥类（冷肿瘤），并且可能代表预测对免疫检查点抑制剂耐药的生物标志物。需要对这些数据进行大规模验证，以便为晚期 HCC 定制免疫治疗。
相似文献
1
Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC.免疫排斥 - Wnt/CTNNB1 类预测 HCC 对免疫治疗的耐药性。
Clin Cancer Res. 2019 Apr 1;25(7):2021-2023. doi: 10.1158/1078-0432.CCR-18-3778. Epub 2019 Jan 7.
2
CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression.CTNNB1 突变通过 miRNA 介导的趋化因子表达调控抑制肝癌中免疫细胞的浸润。
Int Immunopharmacol. 2020 Dec;89(Pt A):107043. doi: 10.1016/j.intimp.2020.107043. Epub 2020 Oct 8.
3
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.Wnt 通路在两种肝癌分子亚型中的激活作用及索拉非尼的实验调节作用。
Clin Cancer Res. 2012 Sep 15;18(18):4997-5007. doi: 10.1158/1078-0432.CCR-11-2322. Epub 2012 Jul 18.
4
AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.AXIN 缺失在人类和小鼠肝细胞中诱导肝癌的发生，而无需 β-连环蛋白的激活。
J Hepatol. 2018 Jun;68(6):1203-1213. doi: 10.1016/j.jhep.2017.12.018. Epub 2018 Mar 7.
5
Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.β-连环蛋白突变型肝细胞癌的形态学异质性：对肿瘤分子分类的影响。
Hum Pathol. 2022 Jan;119:15-27. doi: 10.1016/j.humpath.2021.09.009. Epub 2021 Sep 27.
6
β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.β-连环蛋白激活促进肝癌的免疫逃逸和抗 PD-1 治疗耐药性。
Cancer Discov. 2019 Aug;9(8):1124-1141. doi: 10.1158/2159-8290.CD-19-0074. Epub 2019 Jun 11.
7
Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.乙型肝炎病毒相关肝细胞癌中异常Wnt信号通路的综合分析
World J Gastroenterol. 2015 May 28;21(20):6317-28. doi: 10.3748/wjg.v21.i20.6317.
8
CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma.CTNNB1 改变是肝细胞癌患者免疫治疗预后的潜在生物标志物。
Front Immunol. 2021 Oct 28;12:759565. doi: 10.3389/fimmu.2021.759565. eCollection 2021.
9
LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC.LKB1 信号在 CTNNB1 突变型 HCC 中被激活，并正向调节 β-连环蛋白依赖性 CTNNB1 突变型 HCC。
J Pathol. 2019 Apr;247(4):435-443. doi: 10.1002/path.5202. Epub 2018 Dec 27.
10
β-catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma.β-连环蛋白（CTNNB1）突变与晚期肝细胞癌的预后无关。
Oncology. 2014;87(3):159-66. doi: 10.1159/000362821. Epub 2014 Jul 8.
引用本文的文献
1
Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights.乐伐替尼联合帕博利珠单抗对比化疗治疗晚期子宫内膜癌：疗效与安全性分析
Cureus. 2025 Jul 30;17(7):e89030. doi: 10.7759/cureus.89030. eCollection 2025 Jul.
2
Metabolic genes interaction perturbation network identified and validated CD24 as a novel prognostic gene in hepatocellular carcinoma.代谢基因相互作用扰动网络鉴定并验证CD24为肝细胞癌中的一种新型预后基因。
Discov Oncol. 2025 Aug 27;16(1):1643. doi: 10.1007/s12672-025-03232-5.
3
Beta-Catenin Mutations Can Impact on the Interplay Between Tumor and Immune Cells and Hepatic Microbiota in Hepatocellular Cancer.β-连环蛋白突变可影响肝细胞癌中肿瘤与免疫细胞及肝脏微生物群之间的相互作用。
J Hepatocell Carcinoma. 2025 Aug 1;12:1677-1693. doi: 10.2147/JHC.S524341. eCollection 2025.
4
Noninvasive Tumor Profiling: Quantitative Contrast-Enhanced MRI Markers Predict PD-L1 and CTNNB1 Status in Hepatocellular Carcinoma.非侵入性肿瘤分析：定量对比增强MRI标志物预测肝细胞癌中PD-L1和CTNNB1状态
Radiology. 2025 Aug;316(2):e242750. doi: 10.1148/radiol.242750.
5
Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review.肝细胞癌辅助免疫治疗的进展：综述
Immunotargets Ther. 2025 Jun 25;14:631-654. doi: 10.2147/ITT.S528709. eCollection 2025.
6
Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma.肝细胞癌中对免疫检查点抑制剂原发性和继发性耐药的特征及结局
Cancer Immunol Immunother. 2025 Jun 7;74(8):239. doi: 10.1007/s00262-025-04089-x.
7
Multi-omics and single-cell approaches reveal molecular subtypes and key cell interactions in hepatocellular carcinoma.多组学和单细胞方法揭示了肝细胞癌的分子亚型和关键细胞相互作用。
Front Pharmacol. 2025 May 22;16:1605162. doi: 10.3389/fphar.2025.1605162. eCollection 2025.
8
Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma.通过抑制Wnt信号通路下调PD-L1表达以增强PD-1阻断在肝细胞癌中的疗效。
Biol Direct. 2025 Apr 10;20(1):49. doi: 10.1186/s13062-025-00645-8.
9
Cell-type-specific subtyping of epigenomes improves prognostic stratification of cancer.表观基因组的细胞类型特异性亚型分类改善了癌症的预后分层。
Genome Med. 2025 Apr 3;17(1):34. doi: 10.1186/s13073-025-01453-5.
10
Harnessing Plasma Biomarkers to Predict Immunotherapy Outcomes in Hepatocellular Carcinoma: The Role of cfDNA, ctDNA, and Cytokines.利用血浆生物标志物预测肝细胞癌免疫治疗结果：游离DNA、循环肿瘤DNA和细胞因子的作用
Int J Mol Sci. 2025 Mar 20;26(6):2794. doi: 10.3390/ijms26062794.
本文引用的文献
1
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.肝细胞癌的前瞻性基因分型：下一代测序在将患者与靶向和免疫治疗相匹配方面的临床意义。
Clin Cancer Res. 2019 Apr 1;25(7):2116-2126. doi: 10.1158/1078-0432.CCR-18-2293. Epub 2018 Oct 29.
2
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.索拉非尼辅助治疗 HCC 预防复发的分子预测因子和 3 期 STORM 试验的预后因素。
Gut. 2019 Jun;68(6):1065-1075. doi: 10.1136/gutjnl-2018-316408. Epub 2018 Aug 14.
3
Molecular therapies and precision medicine for hepatocellular carcinoma.肝细胞癌的分子治疗和精准医学。
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616. doi: 10.1038/s41571-018-0073-4.
4
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.基于分子特征鉴定免疫特异的肝细胞癌。
Gastroenterology. 2017 Sep;153(3):812-826. doi: 10.1053/j.gastro.2017.06.007. Epub 2017 Jun 15.
5
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.黑色素瘤内在的β-连环蛋白信号抑制抗肿瘤免疫。
Nature. 2015 Jul 9;523(7559):231-5. doi: 10.1038/nature14404. Epub 2015 May 11.
6
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.肝细胞癌的外显子组测序鉴定出新的突变特征和潜在治疗靶点。
Nat Genet. 2015 May;47(5):505-511. doi: 10.1038/ng.3252. Epub 2015 Mar 30.
7
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
Zotero 插件